Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition |
Yeom, Hojin
(Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University)
Hwang, Sung-Hee (Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University) Han, Byeal-I (Institute for New Drug Development, Incheon National University) Lee, Michael (Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University) |
1 | Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., Facchinetti, V., Sabatini, D. M. and Ballabio, A. (2012) A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095-1108. DOI |
2 | Sullivan, R. J., Hollebecque, A., Flaherty, K. T., Shapiro, G. I., Ahnert, J. R., Millward, M. J., Zhang, W., Gao, L., Sykes, A., Willard, M. D., Yu, D., Schade, A. E., Crowe, K., Flynn, D. L., Kaufman, M. D., Henry, J. R., Peng, S. B., Benhadji, K. A., Conti, I., Gordon, M. S., Tiu, R. V. and Hong, D. S. (2020) A phase I study of LY3009120, a pan-RAF inhibitor, in patients with advanced or metastatic cancer. Mol. Cancer Ther. 19, 460-467. DOI |
3 | Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L. E., Bollag, G. and Trail, P. A. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109. DOI |
4 | Xie, X., Koh, J. Y., Price, S., White, E. and Mehnert, J. M. (2015) Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 5, 410-423. DOI |
5 | Kouraklis, G. and Theocharis, S. (2006) Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol. Rep. 15, 489-494. |
6 | Yang, A., Rajeshkumar, N. V., Wang, X., Yabuuchi, S., Alexander, B. M., Chu, G. C., Von Hoff, D. D., Maitra, A. and Kimmelman, A. C. (2014) Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4, 905-913. DOI |
7 | Zahedi, S., Fitzwalter, B. E., Morin, A., Grob, S., Desmarais, M., Nellan, A., Green, A. L., Vibhakar, R., Hankinson, T. C., Foreman, N. K. and Mulcahy Levy, J. M. (2019) Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. Cell Death Dis. 10, 679. DOI |
8 | Zhang, Z., Singh, R. and Aschner, M. (2016) Methods for the detection of autophagy in mammalian cells. Curr. Protoc. Toxicol. 69, 20.12.1-20.12.26. |
9 | Zhitomirsky, B., Yunaev, A., Kreiserman, R., Kaplan, A., Stark, M. and Assaraf, Y. G. (2018) Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity. Cell Death Dis. 9, 1191. DOI |
10 | Mulcahy Levy, J. M., Zahedi, S., Griesinger, A. M., Morin, A., Davies, K. D., Aisner, D. L., Kleinschmidt-DeMasters, B. K., Fitzwalter, B. E., Goodall, M. L., Thorburn, J., Amani, V., Donson, A. M., Birks, D. K., Mirsky, D. M., Hankinson, T. C., Handler, M. H., Green, A. L., Vibhakar, R., Foreman, N. K. and Thorburn, A. (2017) Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. eLife 6, e19671. DOI |
11 | Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., Sproesser, K., Li, L., Smalley, K. S., Fong, D., Zhu, Y. L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, Y., Luu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S. H., Schlessinger, J., Zhang, K. Y., West, B. L., Powell, B., Habets, G., Zhang, C., Ibrahim, P. N., Hirth, P., Artis, D. R., Herlyn, M. and Bollag, G. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent anti-melanoma activity. Proc. Natl. Acad. Sci. U.S.A. 105, 3041-3046. DOI |
12 | Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T. and Montironi, R. (2018) Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod. Pathol. 31, 24-38. DOI |
13 | Davies, H., Bignell, G., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R. and Futreal, P. A. (2002) Mutations of the B-Raf gene in human cancer. Nature 417, 949-954. DOI |
14 | Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J., Stokoe, D., Gloor, S. L., Vigers, G., Morales, T., Aliagas, I., Liu, B., Sideris, S., Hoeflich, K. P., Jaiswal, B. S., Seshagiri, S., Koeppen, H., Belvin, M., Friedman, L. S. and Malek, S. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435. DOI |
15 | Ahn, J. H. and Lee, M. (2013) Autophagy-dependent survival of mutant B-Raf melanoma cells selected for resistance to apoptosis induced by inhibitors against oncogenic B-Raf. Biomol. Ther. (Seoul) 21, 114-120. DOI |
16 | Algazi, A. P., Othus, M., Daud, A. I., Lo, R. S., Mehnert, J. M., Truong, T. G., Conry, R., Kendra, K., Doolittle, G. C., Clark, J. I., Messino, M. J., Moore, D. F., Jr., Lao, C., Faller, B. A., Govindarajan, R., Harker-Murray, A. H., Dreisbach, L., Moon, J., Grossmann, K. F. and Ribas, A. (2020) Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat. Med. 26, 1564-1568. DOI |
17 | Cantwell-Dorris, E. R., O'Leary, J. J. and Sheils, O. M. (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385-394. DOI |
18 | Choi, K. S. (2012) Autophagy and cancer. Exp. Mol. Med. 44, 109-120. DOI |
19 | Corazzari, M., Fimia, G. M., Lovat, P. and Piacentini, M. (2013) Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. Semin. Cancer Biol. 23, 337-343. DOI |
20 | Chou, T. C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446. DOI |
21 | Dinter, L., Karitzky, P., Kaeubler, T., Niessner, H., Wanke, I., Beissert, S., Meier, F. and Westphal, D. (2019) BRAF/MEK inhibitors induce potent ER stress - Enforced apoptosis in BRAFwt/NRASmut melanoma cells - Insights into mode of action and resistance mechanisms. In: Proceedings of the 16th International Congress of the Society for Melanoma Research, p. 102, 2019 Nov 20-21. The Society for Melanoma Research, Salt Lake City, UT, USA. |
22 | Egan, D. F., Chun, M. G., Vamos, M., Zou, H., Rong, J., Miller, C. J., Lou, H. J., Raveendra-Panickar, D., Yang, C. C., Sheffler, D. J., Teriete, P., Asara, J. M., Turk, B. E., Cosford, N. D. and Shaw, R. J. (2015) Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol. Cell 59, 285-297. DOI |
23 | Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., Nathanson, K. L., Xia, C., Simantov, R., Schwartz, B., Poulin-Costello, M., O'Dwyer, P. J. and Ratain, M. J. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586. DOI |
24 | Holderfield, M., Deuker, M. M., McCormick, F. and McMahon, M. (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 14, 455-467. DOI |
25 | Li, S., Song, Y., Quach, C., Guo, H., Jang, G. B., Maazi, H., Zhao, S., Sands, N. A., Liu, Q., In, G. K., Peng, D., Yuan, W., Machida, K., Yu, M., Akbari, O., Hagiya, A., Yang, Y., Punj, V., Tang, L. and Liang, C. (2019) Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat. Commun. 10, 1693. DOI |
26 | Hwang, S. H., Han, B. I. and Lee, M. (2018) Knockout of ATG5 leads to malignant cell transformation and resistance to Src family kinase inhibitor PP2. J. Cell. Physiol. 233, 506-515. DOI |
27 | Ichimiya, T., Yamakawa, T., Hirano, T., Yokoyama, Y., Hayashi, Y., Hirayama, D., Wagatsuma, K., Itoi, T. and Nakase, H. (2020) Autophagy and autophagy-related diseases: a review. Int. J. Mol. Sci. 21, 8974. DOI |
28 | Kim, N. Y., Han, B. I. and Lee, M. (2016) Cytoprotective role of autophagy against BH3 mimetic gossypol in ATG5 knockout cells generated by CRISPR-Cas9 endonuclease. Cancer Lett. 370, 19-26. DOI |
29 | Luebker, S. A. and Koepsell, S. A. (2019) Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. Front. Oncol. 9, 268. DOI |
30 | Ma, X. H., Piao, S. F., Dey, S., McAfee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., Lazova, R., Klump, V., Pawelek, J. M., Xu, X., Xu, W., Schuchter, L. M., Davies, M. A., Herlyn, M., Winkler, J., Koumenis, C. and Amaravadi, R. K. (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Invest. 124, 1406-1417. DOI |
31 | Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. and Rosen, N. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430. DOI |
32 | Piao, S. and Amaravadi, R. K. (2016) Targeting the lysosome in cancer. Ann. N. Y. Acad. Sci. 1371, 45-54. DOI |
33 | Pisapia, P., Pepe, F., Iaccarino, A., Sgariglia, R., Nacchio, M., Russo, G., Gragnano, G., Malapelle, U. and Troncone, G. (2020) BRAF: a two-faced Janus. Cells 9, 2549. DOI |
34 | Poklepovic, A. and Gewirtz, D. A. (2014) Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. Autophagy 10, 1478-1480. DOI |
35 | Rather, R. A., Bhagat, M. and Singh, S. K. (2020) Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: crosstalk and therapeutic targets in cutaneous melanoma. Mutat. Res. 785, 108321. DOI |
36 | Settembre, C., Di Malta, C., Polito, V. A., Garcia Arencibia, M., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., Sardiello, M., Rubinsztein, D. C. and Ballabio, A. (2011) TFEB links autophagy to lysosomal biogenesis. Science 332, 1429-1433. DOI |
37 | Levy, J. M., Thompson, J. C., Griesinger, A. M., Amani, V., Donson, A. M., Birks, D. K., Morgan, M. J., Mirsky, D. M., Handler, M. H., Foreman, N. K. and Thorburn, A. (2014) Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. Cancer Discov. 4, 773-780. DOI |
38 | Kinsey, C. G., Camolotto, S. A., Boespflug, A. M., Guillen, K. P., Foth, M., Truong, A., Schuman, S. S., Shea, J. E., Seipp, M. T., Yap, J. T., Burrell, L. D., Lum, D. H., Whisenant, J. R., Gilcrease, G. W. r., Cavalieri, C. C., Rehbein, K. M., Cutler, S. L., Affolter, K. E., Welm, A. L., Welm, B. E., Scaife, C. L., Snyder, E. L. and McMahon, M. (2019) Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat. Med. 25, 620-627. DOI |
39 | Lai, F., Guo, S. T., Jin, L., Jiang, C. C., Wang, C. Y., Croft, A., Chi, M. N., Tseng, H. Y., Farrelly, M., Atmadibrata, B., Norman, J., Liu, T., Hersey, P. and Zhang, X. D. (2013) Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis. 4, e655. DOI |
40 | Kimura, S., Noda, T. and Yoshimori, T. (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3, 452-460. DOI |
41 | Lito, P., Rosen, N. and Solit, D. B. (2013) Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409. DOI |
42 | Liu, H., He, Z. and Simon, H. U. (2014) Autophagy suppresses melanoma tumorigenesis by inducing senescence. Autophagy 10, 372-373. DOI |